RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+0.75%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$911M
AUM Growth
+$911M
(-5%)
Cap. Flow
-$18.5M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
30.91%
Holding
97
New
4
Increased
33
Reduced
45
Closed
9
Top Buys
| 1 |
UnitedHealth
UNH
|
$17.9M |
| 2 |
McKesson
MCK
|
$8.23M |
| 3 |
Cooper Companies
COO
|
$7.72M |
| 4 |
Abbott
ABT
|
$6.74M |
| 5 |
Cigna
CI
|
$5.72M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$32.2M |
| 2 |
Johnson & Johnson
JNJ
|
$17.7M |
| 3 |
Medtronic
MDT
|
$9.11M |
| 4 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$6.48M |
| 5 |
Pfizer
PFE
|
$6.46M |
Sector Composition
| 1 | Healthcare | 95.19% |
| 2 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Exact Sciences
EXAS
$9.33B
| $5.96M | 0.65% |
90,000
-20,000
| -18% | -$1.33M |
|
|
ITCI
52
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.89M | 0.65% |
105,000
-20,000
| -16% | -$1.12M |
|
53
Edwards Lifesciences
EW
$47.7B
| $5.71M | 0.63% |
70,000
-74,000
| -51% | -$6.04M |
|
54
Harmony Biosciences
HRMY
$2.16B
| $5.56M | 0.61% |
170,000
-70,000
| -29% | -$2.29M |
|
55
West Pharmaceutical
WST
$17.9B
| $5.11M | 0.56% |
15,000
-10,000
| -40% | -$3.41M |
|
|
IMGN
56
DELISTED
Immunogen Inc
IMGN
| $4.64M | 0.51% |
1,250,000
-250,000
| -17% | -$928K |
|
57
Glaukos
GKOS
$5.42B
| $4.53M | 0.5% |
92,000
+7,000
| +8% | +$345K |
|
|
RCM
58
DELISTED
R1 RCM Inc. Common Stock
RCM
| $4.49M | 0.49% |
300,000
-78,000
| -21% | -$1.17M |
|
59
Iovance Biotherapeutics
IOVA
$800M
| $4.22M | 0.46% |
686,170
-178,208
| -21% | -$1.1M |
|
60
IQVIA
IQV
$31.4B
| $4.09M | 0.45% |
21,000
+1,000
| +5% | +$195K |
|
61
Bio-Techne
TECH
$8.3B
| $3.98M | 0.44% |
55,000
-35,000
| -39% | -$2.54M |
|
62
Health Catalyst
HCAT
$228M
| $3.87M | 0.42% |
340,000
+160,000
| +89% | +$1.82M |
|
|
OLK
63
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $3.8M | 0.42% |
174,300
-20,090
| -10% | -$438K |
|
64
Alkermes
ALKS
$4.95B
| $3.76M | 0.41% |
135,000
-15,000
| -10% | -$417K |
|
65
Phreesia
PHR
$1.81B
| $3.7M | 0.41% |
120,000
-30,000
| -20% | -$926K |
|
|
VRAY
66
DELISTED
ViewRay, Inc.
VRAY
| $3.32M | 0.36% |
1,000,000
| – | – |
|
67
Viking Therapeutics
VKTX
$3.02B
| $3.12M | 0.34% |
+180,000
| New | +$3.12M |
|
68
Relay Therapeutics
RLAY
$709M
| $3.02M | 0.33% |
190,000
-10,000
| -5% | -$159K |
|
69
MeiraGTx Holdings
MGTX
$590M
| $2.8M | 0.31% |
538,986
-16,044
| -3% | -$83.3K |
|
70
NovoCure
NVCR
$1.35B
| $2.62M | 0.29% |
45,000
+10,000
| +29% | +$582K |
|
71
Nuvalent
NUVL
$5.74B
| $2.54M | 0.28% |
100,000
+20,000
| +25% | +$508K |
|
72
Intuitive Surgical
ISRG
$158B
| $2.51M | 0.28% |
10,000
+5,000
| +100% | +$1.26M |
|
73
BridgeBio Pharma
BBIO
$9.91B
| $2.32M | 0.25% |
+135,000
| New | +$2.32M |
|
74
Arvinas
ARVN
$580M
| $2.28M | 0.25% |
85,000
| – | – |
|
75
Agilon Health
AGL
$497M
| $2.1M | 0.23% |
90,000
-165,000
| -65% | -$3.86M |
|